GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Envoy Medical Inc (NAS:COCH) » Definitions » Capex-to-Revenue

Envoy Medical (Envoy Medical) Capex-to-Revenue : 1.85 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Envoy Medical Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Envoy Medical's Capital Expenditure for the three months ended in Mar. 2024 was $-0.11 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.06 Mil.

Hence, Envoy Medical's Capex-to-Revenue for the three months ended in Mar. 2024 was 1.85.


Envoy Medical Capex-to-Revenue Historical Data

The historical data trend for Envoy Medical's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Envoy Medical Capex-to-Revenue Chart

Envoy Medical Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Revenue
0.40 0.92 0.48

Envoy Medical Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only 0.76 0.18 0.78 0.22 1.85

Competitive Comparison of Envoy Medical's Capex-to-Revenue

For the Medical Devices subindustry, Envoy Medical's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Envoy Medical's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Envoy Medical's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Envoy Medical's Capex-to-Revenue falls into.



Envoy Medical Capex-to-Revenue Calculation

Envoy Medical's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.153) / 0.316
=0.48

Envoy Medical's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.109) / 0.059
=1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Envoy Medical  (NAS:COCH) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Envoy Medical Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Envoy Medical's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Envoy Medical (Envoy Medical) Business Description

Traded in Other Exchanges
N/A
Address
4875 White Bear Parkway, White Bear Lake, MN, USA, 55110
Envoy Medical Inc is focused on designing, developing, and marketing fully implantable medical devices that improve hearing. The Company's first commercial product, the Esteem PMA application, is a fully implantable hearing device. The Esteem PMA was cleared in 2010 by the United States Food and Drug Administration. The Company intends to continue to pursue the development of a cochlear implant.